Sanofi set to acquire Kiadis and its cell-based immunotherapy products 02-Nov-2020 By Rachel Arthur Sanofi is eying up the European biopharmaceutical company’s proprietary next generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease therapies.
Sanofi signs €875m deal with Kiadis 13-Jul-2020 By Ben Hargreaves Sanofi looks to supplement its Sarclisa therapy with investigational treatment to treat multiple myeloma.
Kiadis gains NK-cell technology for immunology therapies through CytoSen acquisition 17-Apr-2019 By Maggie Lynch Kiadis Pharma acquires CytoSen Therapeutics and gains NK-cell technology capabilities to complement its own T-cell platform.